Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)

For security reasons, registration is required before you can use this feature.
* Indicates required field